



**FOR IMMEDIATE RELEASE**  
**Embargoed until June 21, 2007 at 7:00 AM EDT**

## **Basketball Hall of Fame Coach Chuck Daly Creates Game Plan to Manage the Symptoms of Benign Prostatic Hyperplasia (BPH)**

*Basketball coaching legend and a leading men's health advocacy organization team up to raise awareness of one of the most common and manageable health problems in older men*

Bridgewater, NJ (June 21, 2007) -- Hall of Fame basketball coach Chuck Daly and a leading men's health organization dedicated to bringing awareness to prostate health issues have teamed up to launch *BPH Game Plan Starts with U*, a national program to encourage screening for and raise awareness of benign prostatic hyperplasia (BPH), commonly known as enlarged prostate.

BPH is a progressive but manageable condition in which the prostate becomes enlarged causing frequent and urgent urination, the need to urinate at night, weak urinary stream and the feeling of incomplete bladder emptying. BPH is one of the most common health problems in older men, affecting more than eight million men in the U.S. About half of all men over age 50 and as many as 90 percent of men over age 70 are affected by BPH.

"As a coach, I face problems head on. So when I was diagnosed with BPH, I made a game plan with my doctor," explains Daly. "I hope that sharing my experiences can help other men to understand that BPH is a common condition and encourage them to work with their doctors to create a game plan of their own."

Daly, famous for coaching the Detroit Pistons to consecutive NBA championships and for coaching the gold medal-winning basketball Dream Team in the 1992 Summer Olympics, has suffered from BPH for more than 20 years. Originally thinking the symptoms were signs of getting older, Daly postponed seeing his doctor until he hit his breaking point – the aggravation of constantly waking up during the night to use the bathroom – sometimes several times a night. Part of Daly's game plan includes managing his symptoms with UROXATRAL<sup>®</sup> (alfuzosin HCl 10 mg).

"While this may be a difficult and sometimes scary subject to talk about, opening a dialogue with your primary care physician about your urinary symptoms is an important first step to effectively manage BPH," said Dr. Michael J. Naslund, Professor of surgery (urology) and director of the Maryland Prostate Center at the University of Maryland School of Medicine. "It's important to note that BPH is not prostate cancer. Although some of the symptoms of BPH and prostate

cancer are similar, having BPH does not seem to increase the chances of developing prostate cancer.”

Through the *BPH Game Plan Starts with U* initiative, Daly is traveling across the country to share his experience with BPH and to encourage men to get screened and talk to their doctors. For more information on BPH and local screenings with Coach Daly, visit [www.talkaboutBPH.com](http://www.talkaboutBPH.com). This Web site also provides tips about how to start a dialogue with your physician, as well as a risk assessment tool, information on BPH and treatment options.

*BPH Game Plan Starts with U* is supported by sanofi-aventis.

### **About Benign Prostatic Hyperplasia (BPH)**

BPH is defined as a progressive condition in which prostate cells grow more rapidly than normal and cause the prostate to become enlarged. About half of all men over age 50 and as many as 90 percent of men over age 70 are affected by BPH. Symptoms of BPH vary, but the most common involve changes or problems with urination that disrupt a man’s personal and professional life with interruptions on a daily basis. Symptoms of BPH include frequent and urgent urination, the need to urinate at night, weak urinary stream and feeling of incomplete bladder emptying. If left untreated, men could be at risk for sexual dysfunction, acute urinary retention, bladder infections, bladder stones, and even kidney damage.

### **About PCEC:**

The Prostate Cancer Education Council (PCEC) was founded in 1989, and is a non-profit 501-3c organization. The Council is comprised of a consortium of leading physicians, health educators, scientists and prostate health advocates. PCEC’s mission is to save lives through awareness and the education of men, the women in their lives as well as the medical community about the prevalence of prostate conditions, the importance of early diagnosis, available treatment options and other men's health issues.

### **About UROXATRAL**

UROXATRAL (alfuzosin HCl), is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). UROXATRAL, a selective alpha1-blocker (alpha1 receptor subtype), works by relieving symptoms of urinary obstruction by relaxing the tone of the smooth muscle surrounding the prostate gland, bladder neck and prostatic urethra.

### **Important Safety Information**

Do not take UROXATRAL if you have liver problems or if you are taking the antifungal drugs like ketoconazole or itraconazole, or HIV drugs like ritonavir.

UROXATRAL can cause a sudden drop in blood pressure especially when starting treatment. This may lead to fainting, dizziness, and lightheadedness. Do not drive, operate machinery, or do any dangerous activity until you know how UROXATRAL will affect you. This is especially important if you already have a problem with low blood pressure or take medicines to treat high blood pressure.

Before taking UROXATRAL, tell your doctor if you have kidney problems.

Also tell your doctor if you or any family member(s) have or take medications for, a rare heart condition known as congenital prolongation of the QT interval.

BPH and prostate cancer can cause the same symptoms. However UROXATRAL is not a treatment for prostate cancer.

The most common side effects with UROXATRAL are dizziness, upper respiratory tract infection, headache and tiredness.

Please see accompanying full prescribing information. Please see [www.uroxatral.com](http://www.uroxatral.com) for additional product information.

**About sanofi-aventis:**

Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

**Forward Looking Statements:**

*This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.*

###

Media contact: Noelle Boyd , 908-981-6489, [noelle.boyd@sanofi-aventis.com](mailto:noelle.boyd@sanofi-aventis.com)